Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Apolipoprotein E (APOE) is a key cholesterol carrier in the brain, influencing neuronal signaling, neuroinflammation, and metabolism.
• The APOE Ɛ4 allele significantly increases Alzheimer's disease (AD) risk, while the Ɛ2 allele is protective.
• APOE4's role in AD pathogenesis involves exacerbating amyloid-beta plaque burden and potentially tau pathology, with other mechanisms also implicated.

Purpose of the Study:

• To review current and future therapeutic strategies targeting APOE4 for Alzheimer's disease prevention and treatment.
• To understand the molecular mechanisms underlying APOE-related genetic risk in AD.
• To explore methods for disrupting pathological APOE4 functions while preserving beneficial APOE functions.

Main Methods:

• Review of existing cellular and animal models investigating APOE function in AD.
• Analysis of studies examining the impact of APOE isoforms on amyloid-beta and tau pathology.
• Synthesis of research on potential therapeutic interventions targeting APOE4.

Main Results:

• APOE4 exacerbates amyloid-beta plaque burden and may enhance tau pathogenesis in an isoform-dependent manner.
• APOE4 may increase AD risk through mechanisms independent of direct Aβ or tau modulation.
• The indirect effects of plasma APOE on central nervous system function are not fully understood.

Conclusions:

• APOE significantly impacts multiple signaling pathways relevant to AD.
• Targeting APOE4 offers a promising therapeutic avenue for Alzheimer's disease.
• Developing strategies that selectively disrupt detrimental APOE4 functions is crucial for effective AD treatment.